Press Releases

See our recent news and announcements below. If you have any questions or for media inquiries, please contact for assistance or see specified media contact details within each release.

Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology

Waltham, MA, May 20, 2021

Pyramid Biosciences, Inc., a clinical-stage, biotechnology company developing novel precision therapies, announced that it has commenced a Phase 1 clinical study for its therapeutic candidate PBI-100, a first-in-class topical treatment targeting mild to moderate psoriasis in patients. Psoriasis is an immune-mediated skin disease1, where an overactive immune system causes a rapid increase in keratinocyte production that can lead to raised, flaking skin lesions. People living with psoriasis report symptoms such as itching, burning and stinging. [click to read more]